Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema (right eye)
ICD-10 E09.3511 is a billable code used to indicate a diagnosis of drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema (right eye).
E09.3511 refers to diabetes mellitus that has been induced by drugs or chemicals, leading to significant complications such as proliferative diabetic retinopathy and macular edema specifically in the right eye. This condition arises when certain medications, such as corticosteroids or antipsychotics, disrupt normal glucose metabolism, resulting in hyperglycemia and subsequent diabetes. Proliferative diabetic retinopathy is characterized by the growth of new blood vessels in the retina, which can lead to vision loss. Macular edema, a common complication, occurs when fluid accumulates in the macula, the central part of the retina responsible for sharp vision. Patients may present with symptoms such as blurred vision or difficulty seeing colors. Management typically involves controlling blood glucose levels, monitoring HbA1c levels, and possibly using laser therapy or anti-VEGF injections to address retinal complications. Regular eye examinations are crucial for early detection and treatment of these complications.
Detailed medication history, HbA1c levels, and management plans.
Patients presenting with new-onset diabetes due to medication, requiring insulin management.
Ensure clear documentation of the drug responsible for diabetes and its management.
Detailed eye examination findings, including retinal imaging results.
Patients with diabetic retinopathy requiring treatment and follow-up.
Document specific findings related to macular edema and treatment interventions.
Used for treatment of proliferative diabetic retinopathy.
Document indication for laser treatment and prior retinal findings.
Ophthalmologists should ensure detailed documentation of retinal status pre- and post-procedure.
Specifying the eye involved is crucial for treatment planning and monitoring, as it affects the management of diabetic retinopathy and potential interventions.
